Hyperparathyroïdie secondaire et anémie. Effets d’un calcimimétique sur le contrôle de l’anémie des hémodialysés chroniques. Étude pilote
Authors:
- Ignace MpioIMIgnace Mpio
- Nourredine BoumendjelNBNourredine Boumendjel
- Husseyin KaraaslanHKHusseyin Karaaslan
- Walid ArkoucheWAWalid Arkouche
- Alexandra LenzALAlexandra Lenz
- Carlos CardozoCCCarlos Cardozo
- Jorge CardozoJCJorge Cardozo
- Myriam Pastural-ThaunatMPMyriam Pastural-Thaunat
- Denis FouqueDFDenis Fouque
- Jacques SilouJSJacques Silou
- David AttafDADavid Attaf
- Maurice LavilleMLMaurice Laville
- 1 July 2011
- journal article
- research article
- Published by JLE in Nephrologie & Therapeutique
- Vol. 7 (4) , 229-236
Abstract
The main cause of resistance to erythropoiesis-stimulating agents (ESA) used for treatment of anemia in chronic hemodialysed patients (CHP) is the iron deficiency, absolute or functional. Secondary hyperparathyroidism (SHPT) is a secondary factor of resistance. Indeed, it has been reported in the literature an improvement of anemia parameters after surgical parathyroidectomy (PTX). The objective of this study is to assess in CHP, the impact of the correction of SHPT by a calcimimetic, cinacalcet (CI), (which is considered as a pharmacological PTX) on the response to ESA, measured by the erythropoietin resistance index (ERI). Twenty-two CHP with severe SHPT documented by an intact parathyroid hormone (iPTH) above 800pg/mL were included in this prospective pilot study. Mineral bone metabolism, anemia and nutritional parameters were measured baseline and after 6 months of treatment by CI. The effect on anemia was assessed at the end of study by the ERI, the change in Hb concentration, and the proportion of patients with Hb levels above 11g/dL. At the end of study there was a significant decrease (M6 vs M0) in iPTH (1302 vs 674pg/mL or -48%, p=0.006), serum calcium (2.39 vs 2.15mmol/L or -10%), serum phosphate (2 vs 1.7mmol/L or -15%), serum calcium-phosphorus product (CaxP) (4.8 vs 3.8mmol(2)/L(2) or - 20% (p4.4mmol(2)/L(2) (64 vs 32%, p<0.05). The level of bone alkaline phosphatase remained stable during the study (28 vs 27 IU/L). The Hb levels increased from 11 to 11.4g/dL, as did the proportion of patients whose Hb concentration reached 11g/dL or higher (50 vs 70%, p<0.05) without important change of the median weekly ESA dosis in the majority of patients, 18 cases (81%) vs four (19%). Two subgroups were identified from the median decreases in iPTH (delta iPTH) between M0 and M6, Group 1 (delta iPTH≥400pg/mL, n=10) and group 2 (delta iPTH<400pg/mL, n=12): in group 1, we found a correlation between the decrease in iPTH by CI and the stability or decrease in ERI (group 1), at comparable dose of dialysis, nutritional and iron intakes and inflammatory profiles; in group 2 without a significant effect of CI on PTH reduction the levels of ERI and ESA dosis were more elevated. A treatment by calcimimetic improves the control of anemia by ESA in CHP and interferes positively on a cause of secondary resistance to ESA represented by SHPT. The mechanism of these effects could be linked to the decreased of bone marrow fibrosis and inflammation and to the triptych formed by the reduction in iPTH, CaxP and phosphate.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacologic modulation of the calcium-sensing receptor enhances hematopoietic stem cell lodgment in the adult bone marrowBlood, 2011
- Inter-method variability in PTH measurement: Implication for the care of CKD patientsKidney International, 2006
- Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis PatientsJournal of the American Society of Nephrology, 2006
- Therapeutic Use of CalcimimeticsAnnual Review of Medicine, 2006
- Calcimimetics and calcilytics—fooling the calcium receptorThe Lancet, 2005
- USRDS 2004 annual data reportAmerican Journal of Kidney Diseases, 2005
- Osteoblastic cells regulate the haematopoietic stem cell nicheNature, 2003
- Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS)Kidney International, 2003
- Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: Role of dietary phosphateKidney International, 1999
- Myelofibrosis Secondary to Renal OsteodystrophyNephron, 1996